Brief: Kancera Starts Study In COVID-19 Patients

Novakand Pharma AB

01/10/2020 15:47

Oct 1 (Reuters) - Kancera AB  KANC.ST :
    * KANCERA STARTS STUDY IN COVID-19 PATIENTS
    * STUDY AIMS TO STUDY EFFECT OF KAND567 ON IMMUNE SYSTEM,
LUNG
FUNCTION AND REHABILITATION
    * RESULTS FROM STUDY WILL BE ANALYZED AND COMMUNICATED ON
TWO
OCCASIONS, FIRST AFTER ALL PATIENTS HAVE UNDERGONE SAMPLING
AFTER DAY 7, AND SECOND AFTER DAY 90
    * STUDY IS CARRIED OUT IN COLLABORATION WITH CAPIO ST.
GÖRAN'S
HOSPITAL AND PETTER BRODIN'S RESEARCH GROUP AT SCILIFELAB

Source text for Eikon:  ID:nWkr4vbtVD 
Further company coverage:  KANC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))